Literature DB >> 16545139

Expression profile of mucins (MUC2, MUC5AC and MUC6) in Helicobacter pylori infected pre-neoplastic and neoplastic human gastric epithelium.

Subramani Durai Babu1, Venkataraman Jayanthi, Niranjali Devaraj, Celso A Reis, Halagowder Devaraj.   

Abstract

BACKGROUND: Helicobacter pylori (H. pylori) causes gastritis and intestinal metaplasia (IM) that may evolve to gastric carcinoma. The objective of this study was to compare the profile of mucins in the progressive stages of H. pylori infected pre-neoplastic and neoplastic human gastric epithelium. We used a panel of monoclonal antibodies with well-defined specificities of MUC2, MUC5AC and MUC6 to characterize the expression pattern of mucins by immunohistochemistry.
METHODS: RUT and ELISA were down for H. pylori confirmation. Human gastric biopsy sections were stained using immunohistochemistry with MUC2, MUC5AC and MUC6 antibodies.
RESULTS: MUC5AC was expressed in the superficial epithelium and the upper part of the gastric pits. MUC6 expression was detected in the lower part of the gastric glands. MUC2 was expressed in intestinal metaplasia, mostly in goblet cells. The mucin expression profile in the progressive stages of H. pylori infected human gastric epithelium allows the identification of intestinal metaplasia, which is characterized by a decreased expression of the gastric mucins (MUC5AC and MUC6) and de novo expression of MUC2.
CONCLUSION: In conclusion, our results suggest that there is altered expression of MUC5AC and MUC6 together with the aberrant expression of MUC2 in intestinal metaplasia, during the process of gastric carcinogenesis. The present study indicates that the MUC2 mucin expression pattern is a reliable marker of intestinal metaplasia, which appears in the context of H. pylori infected individuals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16545139      PMCID: PMC1479362          DOI: 10.1186/1476-4598-5-10

Source DB:  PubMed          Journal:  Mol Cancer        ISSN: 1476-4598            Impact factor:   27.401


Background

Helicobacter pylori colonizes human gastric mucosa and causes gastritis and intestinal metaplasia (IM), which may evolve towards gastric carcinoma [1-3]. H. pylori infection was established as a type I human carcinogen in IARC [4]; it was recently shown that the bacteria are also capable of inducing gastritis, IM, and gastric carcinoma in Mongolian gerbils [5-8]. In humans, H. pylori also colonizes the duodenal mucosa whenever there is gastric metaplasia [9]. H. pylori infection in human is therefore dependent on the gastric microenvironment, which is determined to a large extent by the mucin and carbohydrate composition of the gastric mucin layer. Mucins are heavily glycosylated glycoproteins that are the major components of the mucous viscous gel covering the surface epithelial tissues [10]. To date, nine distinct epithelial mucin genes (MUC1, 2, 3, 4, 5AC, 5B, 6, 7, and 8) have been identified [11-21]. In situ hybridization and immunohistochemical studies have shown that these mucins are differentially expressed in epithelia with cell type specificity [21-24]. The normal gastric mucosa shows cell types specific expression of MUC1, MUC5AC, and MUC6, with first two mucins found in the superficial epithelium and MUC6 in the deep glands [22,25,26]. MUC6 is mainly expressed in gastric mucosa. The normal gastric mucosa does not express MUC2 [25,27]. Changes in the expression levels and glycosylation patterns of mucins have been associated with several diseases, including carcinomas [27-31]. In gastric cancer, alterations in mucin polypeptide have been reported: loss of expression of MUC5AC [23,26,32], increased mucin heterogenesity [23]. These observations suggest that mucin alterations can be regarded as "molecular" markers of malignant transformation of gastric mucosa. Further more, a recently published investigation strongly suggested MUC5AC as a putative H. pylari receptor [33,34]. In this present study, we have characterized the pattern of mucins expression in the progressive stages of H. pylori infected human gastric carcinoma. We have used a comprehensive panel of monoclonal antibodies, with well-characterized specificities directed to MUC2, MUC5AC and MUC6 mucins.

Results

Expression pattern of MUC2, MUC5AC and MUC6 mucins in normal gastric mucosa

MUC5AC was highly expressed in foveolar epithelium and mucous neck cells of antrum (> 75%, Fig. 1b; Fig. 3b; Table 2). Expression of MUC6 was detected in the glands of the antrum (> 75%, Fig. 1c; Fig. 3c; Table 3) and MUC2 was not detected in normal gastric mucosa (Fig. 1a; Fig. 3a; Table 2).
Figure 1

Immunohistochemical staining of MUC2, MUC5AC and MUC6 mucins in . a. MUC2 staining of normal gastric mucosa (Original magnification ×100). b. MUC5AC staining of normal gastric mucosa (Original magnification ×100). c. MUC6 staining of normal gastric mucosa (Original magnification ×100). d. MUC2 staining of Atrophic gastritis (Original magnification ×100). e. MUC5AC staining of Atrophic gastritis (Original magnification ×100). f. MUC6 staining of Atrophic gastritis (Original magnification ×100). g. MUC2 staining of Intestinal metaplasia (Original magnification ×100). h. MUC5AC staining of Intestinal metaplasia (Original magnification ×100).

Figure 3

Expression pattern of mucins (MUC2, MUC5AC and MUC6) in . a. MUC2 expression in H. pylori infected pre-neoplastic and neoplastic human gastric epithelium. b. MUC5AC expression in H. pylori infected pre-neoplastic and neoplastic human gastric epithelium. c. MUC6 expression in H. pylori infected pre-neoplastic and neoplastic human gastric epithelium.

Table 2

Expression of mucins (MUC2, MUCSAC and MUC6) in H. pylori infected pre-neoplastic and neoplastic human gastric epithelium

StagesH. pyloriMUC2 ExpressionMUC5AC ExpressionMUC6 Expression

NP-++++++++++-++++++++++-++++++++++
Normal (n = 7)7-n = 7 (100%)-------n = 2 (28.6%)n = 5 (71.4%)---1 (14.3%)6 (85.7%)
Atrophic gastritis (n = 26)-26n = 22 (84.6%)n = 4 (15.4%)-----1 (38%)13 (50%)12 (46.2%)--1 (3.8%)15 (57.7%)10 (38.5%)
Intestinal metaplasia (n = 21)-21--n = 9 (42.9%)n = 12 (57.1%)**--1 (4.8%)16 (76.2%)**4 (19%)--5 (23.8%)14 (66.7%)**2 (9.5%)-
Dysplasia (n = 17)-17-n = 5 (29.4%)n = 11 (64.7%)n = 1 (5.9%)--3 (17.6%)10 (58.8%)4 (23.5%)--3 (17.6%)11 (64.7%)3 (17.3%)-
Carcinoma (n = 36)-36-22 (61.1%)14 (38.9%)---28 (77.8%)8 (22.2%)--12 (33.3%)17 (47.2%)7 (19.4%)--

N – negative - (> 5%) negative

P – positive + (5–25%) few positive cells

n – No. of cases ++ (25–50%) well-defined area

+++ (50–75%) extensive area stained

++++ (75–100%) most of the cells stained

**p < 0.00, *p < 0.05 (Significant difference in expression)

Immunohistochemical staining of MUC2, MUC5AC and MUC6 mucins in . a. MUC2 staining of normal gastric mucosa (Original magnification ×100). b. MUC5AC staining of normal gastric mucosa (Original magnification ×100). c. MUC6 staining of normal gastric mucosa (Original magnification ×100). d. MUC2 staining of Atrophic gastritis (Original magnification ×100). e. MUC5AC staining of Atrophic gastritis (Original magnification ×100). f. MUC6 staining of Atrophic gastritis (Original magnification ×100). g. MUC2 staining of Intestinal metaplasia (Original magnification ×100). h. MUC5AC staining of Intestinal metaplasia (Original magnification ×100). Immunohistochemical staining of MUC2, MUC5AC and MUC6 mucins in . a. MUC6 staining of Intestinal metaplasia (Original magnification ×100). b. MUC2 staining of dysplasia (Original magnification ×100). c. MUC5AC staining of dysplasia (Original magnification ×100). d. MUC6 staining of dysplasia (Original magnification ×100). e. MUC2 staining of carcinoma (Original magnification ×100). f. MUC5AC staining of carcinoma (Original magnification ×100). g. MUC6 staining of carcinoma (Original magnification ×100). Expression pattern of mucins (MUC2, MUC5AC and MUC6) in . a. MUC2 expression in H. pylori infected pre-neoplastic and neoplastic human gastric epithelium. b. MUC5AC expression in H. pylori infected pre-neoplastic and neoplastic human gastric epithelium. c. MUC6 expression in H. pylori infected pre-neoplastic and neoplastic human gastric epithelium. Specificities, origins and dilutions of the monoclonal antibodies. Expression of mucins (MUC2, MUCSAC and MUC6) in H. pylori infected pre-neoplastic and neoplastic human gastric epithelium N – negative - (> 5%) negative P – positive + (5–25%) few positive cells n – No. of cases ++ (25–50%) well-defined area +++ (50–75%) extensive area stained ++++ (75–100%) most of the cells stained **p < 0.00, *p < 0.05 (Significant difference in expression)

Immunodetection of mucins in atrophic gastritis

There was expression of MUC5AC in all the cases of columnar cells (Fig. 1e; Fig. 3b; Table 2). The percentage of stained cells varied from case to case, in most cases, there was a trend for higher number of cells expressing MUC5AC (>75%) in the superficial part of the metaplastic glands than in deep part. MUC6 was detected in columnar cells (>50%; Fig. 1f; Fig. 3c; Table 2) and MUC2 was not detected in atrophic gastritis (Fig. 1d).

Immunodetection of mucins in intestinal metaplasia

There was decreased level expression of MUC5AC and MUC6 in all the cases (>50%), both in goblet and in columnar cells (Fig. 1h, Fig. 2a; Fig. 3b, Fig. 3c; Table 2). The percentage of stained cells varied from case to case, de novo expression of intestinal mucin MUC2 was observed (>75%), and its expression displayed a diffuse cytoplasmic pattern in goblet cells (Fig. 1g; Fig. 3a; Table 2).
Figure 2

Immunohistochemical staining of MUC2, MUC5AC and MUC6 mucins in . a. MUC6 staining of Intestinal metaplasia (Original magnification ×100). b. MUC2 staining of dysplasia (Original magnification ×100). c. MUC5AC staining of dysplasia (Original magnification ×100). d. MUC6 staining of dysplasia (Original magnification ×100). e. MUC2 staining of carcinoma (Original magnification ×100). f. MUC5AC staining of carcinoma (Original magnification ×100). g. MUC6 staining of carcinoma (Original magnification ×100).

Immunodetection of mucins in dysplasia

There was decreased level expression of MUC5AC and MUC6, than intestinal metaplasia (>50%). MUC5AC and MUC6 displayed a diffuse cytoplasmic expression pattern in columnar cells (Fig. 2c; Fig. 2d; Fig. 3d; Fig. 3; Table 2). MUC2 expression displayed a diffuse cytoplasmic pattern in goblets cells (>50%, Fig. 2b; Fig 3a; Table 2).

Immunodetection of mucins in carcinoma

MUC5AC and MUC6 expression were frequently observed in early carcinoma (>50%) than advanced carcinomas (>25%). In advanced carcinomas, we observed a trend for decreased immunoreactivity in deep areas than in the superficial areas. MUC5AC and MUC6 expressions were decreased in advanced carcinomas (>25%; Fig. 3a; Fig. 3b; Fig. 3c; Fig. 2e, Fig. 2f, Fig. 2g; Table 2).

Discussion

In this present study, we have shown that the pattern of mucins expression in the progressive stages of H. pylori infected human gastric epithelium. Mucins are expressed with a cell- and tissue-specific pattern in normal tissue. Alterations of the expression pattern of mucins have been described in carcinomas as well as in their precursor lesions; in the latter, altered mucin carbohydrate and peptide moieties may constitute molecular markers of increased risk of malignant transformation [27,35,36,38-40]. In agreement with previous studies reporting the distribution of mucins in normal stomach, we found MUC5AC is highly expressed in foveolar cells of antrum, as reported [26,27,32,37-39]. We also found that MUC6 is expressed in mucous cells of the neck zone in pyloric glands of the antrum with similar pattern to that described previously [22,23,47]. The expression of MUC2 was usually not detected in normal gastric mucosa as described in the previous reports [25,27,40]. Intestinal metaplasia is one of the lesions identified in the cascade of event that precedes the development of gastric carcinoma [41]. Intestinal metaplasia comprises the replacement of the gastric mucosa by an epithelium that resembles histologically the intestinal mucosa. Altered mucin expression patterns have been observed in H. pylori infected intestinal metaplasia, including under expression of MUC5AC and MUC6 and de novo expression of MUC2 mostly in goblet cells [30,48]. These results support the assumption that the intestinal metaplasia does represent a differentiation of the mucosa toward a intestinal phenotype [42,43]. The decreased expression of MUC5AC and MUC6 mucin in gastric carcinomas were confirmed in the present study. The expression of MUC5AC in early gastric carcinoma of the present series, regardless of the histological type of the tumors, contrasts with the decreased level expression of MUC5AC immunoreactivity in almost half of the advanced carcinomas which suggest that all gastric carcinomas retain at least some cells with a gastric phenotype during the first steps of neoplastic development (26). This assumption is further supported by the decreased immunoreactivity in deep areas compared with superficial areas of the advanced carcinomas. These results are in agreement with previous results showing that gastric cancer progression is accompanied by alteration of the expression of several mucin genes [14]. Finally, we observed that the intestinal mucin MUC2 is expressed in every intestinal metaplasia, which is a lesion that appears during the process of gastric carcinogenesis in the context of H. pylori infected individuals.

Conclusion

Although H. pylori has been classified as a class I carcinogen by the IARC [4] the mechanism of gastric carcinogenesis remains poorly understood. In pre-neoplastic gastric mucosa, the expression of all the three mucin antigens did not appear to correlate with the severity of inflammation and H. pylori status. Results from the present study may suggest that H. pylori infection acts as an initiator of this carcinogenesis cascade by inducing inflammation and, in some cases, the subsequent metaplastic change. Intestinal metaplasia is accompanied by the induction of expression MUC2 and decreased expression of MUC5AC and MUC6. These alterations may favor the development of gastric carcinoma. The present study suggests that MUC2 is a marker of intestinal metaplasia and may be used for the early detection of this lesion in H. pylori infected pre-neoplastic human gastric epithelium.

Materials and methods

Tissue samples

Fifty nine gastric biopsy specimens and 3 ml of blood were obtained from Stanley Medical College and Hospital, Chennai. All biopsy tissue samples were collected after informed consent. This study was carried out after obtaining clearance from the ethical board of the hospital. All biopsy specimens were fixed in 10% buffered formalin and routinely embedded in paraffin wax. 4 μm thin serial sections were cut and used for immunohistochemistry. H. pylori infection was confirmed by RUT and ELISA [43]. Hematoxylin and Eosin stained sections were used to classify gastritis graded according to revised Sydney classification [44], gastric tumors according to the classification of Lauren [45] and WHO classification [46]. We studied 7 cases of normal Human gastric epithelium (7 biopsies), 26 cases of Atrophic gastritis (26 biopsies), 21 cases of Intestinal metaplasia (21 biopsies), 17 cases of dysplasia (17 biopsies) and 36 cases of carcinoma in which 21 cases early carcinoma and 15 cases advanced carcinoma (16 biopsies and 20 surgical specimens).

Monoclonal antibodies

A panel of three monoclonal antibodies was used to determine the expression of mucins (MUC2, MUC5AC and MUC6). The specificities, references and dilutions of the antibodies are listed in Table 1.
Table 1

Specificities, origins and dilutions of the monoclonal antibodies.

Monoclonal antibodySpecificityReferenceDilution
PMH1MUC2Reis et al [11]Undiluted
CLH2MUC5ACReis et al [12]1:2
CLH5MUC6Reis et al [10]1:2

Immunohistochemistry

Sections from normal, pre-neoplastic and neoplastic gastric tissues were immuno stained according to Reis et al [47] with slight modifications. Sections designed for neuraminidase treatment were washed twice in phosphate buffered saline (PBS), pH 7.4 and incubated with neuraminidase from clostridium perfringens Type VI (Sigma; St Louis, MO) diluted in 0.1 M Na-acetate buffer, pH 5.5 to a final concentration of 0.1 U/ml. The incubation was carried out for 2 h at 37°C and was followed by three washings in ice-cold PBS. Sections were treated with 0.5% H2O2 in methanol for 30 min, followed by 20 min of incubation with rabbit non-immune serum. Sections were rinsed and incubated with primary antibody (Table 1), over night at 4°C. The sections were rinsed and incubated with HRP conjucated rabbit anti-mouse secondary antibody (1:100 dilution) for 1 h followed by rinsing with PBS and developing with 0.05% 3,3'-diaminobenzidine tetrahydrochloride (DAB) (SRL, Mumbai, India) freshly prepared in PBS containing 0.1% H2O2. Sections were counter stained with hematoxylin, dehydrated, and mounted. All series including positive and negative controls were performed by substitution of the primary mAbs with immunoglobulins of the same class and at the same concentration.

Scoring of mucins expression in H. pylori infected pre-neoplastic and neoplastic human gastric tissues

A semi quantitative approach was used to score the immunostaining of human gastric tissues. The slides were examined under light microscope, every 100 cells were scored in five different fields and the results were expressed as mean percentage. (-), negative; +, few positive cells (<25%); ++ well-defined areas with positive cells (25–50%); +++, extensive areas with positive cells (50–75%); ++++, most cells stained (>75%).

Statistics

Data analysis was performed using statistical software package SPSS 10.0 for windows. The Chi-Square test or Fisher's exact test was used to analyze differences in frequencies. Spearman's correlation test was used to analyze correlation between parameters. P < 0.05 was considered statistically significant.

Abbreviations

DAB – 3,3'-diaminobenzidine tetra hydrochloride; ELISA – Enzyme-linked immunosorbent assay; HRP – Horseradish peroxidase; IARC – International Agency for Research on Cancer; IM – Intestinal metaplasia; mAbs – Monoclonal antibodies; PBSPhosphate buffered saline; WHO – World Health Organization; RUT – Rapid Urea Test.

Authors' contributions

SDB carried out all experiments along with the designing and coordination of HD. VJ provided patients data and specimens. HD reviewed the immunohistochemical results and ND, CAR provided suggestion for the finalization of this paper. All authors read and approved the final manuscript.
  44 in total

Review 1.  Mucin glycoproteins in neoplasia.

Authors:  Y S Kim; J Gum; I Brockhausen
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

Review 2.  Glycosylation patterns of mucins in colonic disease.

Authors:  A P Corfield; N Myerscough; M Gough; I Brockhausen; R Schauer; C Paraskeva
Journal:  Biochem Soc Trans       Date:  1995-11       Impact factor: 5.407

3.  Molecular cloning of human intestinal mucin cDNAs. Sequence analysis and evidence for genetic polymorphism.

Authors:  J R Gum; J C Byrd; J W Hicks; N W Toribara; D T Lamport; Y S Kim
Journal:  J Biol Chem       Date:  1989-04-15       Impact factor: 5.157

Review 4.  A human model of gastric carcinogenesis.

Authors:  P Correa
Journal:  Cancer Res       Date:  1988-07-01       Impact factor: 12.701

5.  T/Tn pancarcinoma autoantigens: fundamental, diagnostic, and prognostic aspects.

Authors:  G F Springer; P R Desai; M Ghazizadeh; H Tegtmeyer
Journal:  Cancer Detect Prev       Date:  1995

Review 6.  Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994.

Authors:  M F Dixon; R M Genta; J H Yardley; P Correa
Journal:  Am J Surg Pathol       Date:  1996-10       Impact factor: 6.394

7.  A confirmatory report for the close interaction of Helicobacter pylori with gastric epithelial MUC5AC expression.

Authors:  Belma Kocer; Murat Ulas; Yucel Ustundag; Sibel Erdogan; Melih Karabeyoglu; Osman Yldrm; Bülent Unal; Omer Cengiz; Atilla Soran
Journal:  J Clin Gastroenterol       Date:  2004-07       Impact factor: 3.062

8.  Aberrant expression of a human mucin gene (MUC5AC) in rectosigmoid villous adenoma.

Authors:  M P Buisine; A Janin; V Maunoury; J P Audié; M P Delescaut; M C Copin; J F Colombel; P Degand; J P Aubert; N Porchet
Journal:  Gastroenterology       Date:  1996-01       Impact factor: 22.682

9.  MUC6 apomucin shows a distinct normal tissue distribution that correlates with Lewis antigen expression in the human stomach.

Authors:  C De Bolós; M Garrido; F X Real
Journal:  Gastroenterology       Date:  1995-09       Impact factor: 22.682

10.  Mucin gene expression in normal, preneoplastic, and neoplastic human gastric epithelium.

Authors:  S B Ho; L L Shekels; N W Toribara; Y S Kim; C Lyftogt; D L Cherwitz; G A Niehans
Journal:  Cancer Res       Date:  1995-06-15       Impact factor: 12.701

View more
  27 in total

Review 1.  The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases.

Authors:  Helena Tlaskalová-Hogenová; Renata Stěpánková; Hana Kozáková; Tomáš Hudcovic; Luca Vannucci; Ludmila Tučková; Pavel Rossmann; Tomáš Hrnčíř; Miloslav Kverka; Zuzana Zákostelská; Klára Klimešová; Jaroslava Přibylová; Jiřina Bártová; Daniel Sanchez; Petra Fundová; Dana Borovská; Dagmar Srůtková; Zdeněk Zídek; Martin Schwarzer; Pavel Drastich; David P Funda
Journal:  Cell Mol Immunol       Date:  2011-01-31       Impact factor: 11.530

2.  MUC6 down-regulation correlates with gastric carcinoma progression and a poor prognosis: an immunohistochemical study with tissue microarrays.

Authors:  Huachuan Zheng; Hiroyuki Takahashi; Takahiko Nakajima; Yoshihiro Murai; Zhengguo Cui; Kazuhiro Nomoto; Koichi Tsuneyama; Yasuo Takano
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-29       Impact factor: 4.553

3.  Helicobacter pylori infection impairs the mucin production rate and turnover in the murine gastric mucosa.

Authors:  Nazanin Navabi; Malin E V Johansson; Sukanya Raghavan; Sara K Lindén
Journal:  Infect Immun       Date:  2012-12-28       Impact factor: 3.441

4.  Muc-2-deficient mice display a sex-specific, COX-2-related impairment of gastric mucosal repair.

Authors:  John L Wallace; Linda Vong; Poonam Dharmani; Vikas Srivastava; Kris Chadee
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

Review 5.  Role of mucins in the skin during benign and malignant conditions.

Authors:  Subhankar Chakraborty; Neelima Bonthu; Benjamin J Swanson; Surinder K Batra
Journal:  Cancer Lett       Date:  2010-12-13       Impact factor: 8.679

6.  Helicobacter pylori urease and flagellin alter mucin gene expression in human gastric cancer cells.

Authors:  Michaël Perrais; Christel Rousseaux; Marie-Paule Ducourouble; René Courcol; Pascal Vincent; Nicolas Jonckheere; Isabelle Van Seuningen
Journal:  Gastric Cancer       Date:  2013-05-24       Impact factor: 7.370

7.  A comprehensive analysis of common genetic variation in MUC1, MUC5AC, MUC6 genes and risk of stomach cancer.

Authors:  Yanbin Jia; Christina Persson; Lifang Hou; Zongli Zheng; Meredith Yeager; Jolanta Lissowska; Stephen J Chanock; Wong-Ho Chow; Weimin Ye
Journal:  Cancer Causes Control       Date:  2010-02       Impact factor: 2.506

Review 8.  Polymorphisms in mucin genes in the development of gastric cancer.

Authors:  Rong Wen; Fang Gao; Cheng-Jiang Zhou; Yan-Bin Jia
Journal:  World J Gastrointest Oncol       Date:  2015-11-15

9.  Gastric mucus alterations associated with murine Helicobacter infection.

Authors:  Julia M Schmitz; Carolyn G Durham; Samuel B Ho; Robin G Lorenz
Journal:  J Histochem Cytochem       Date:  2009-01-19       Impact factor: 2.479

10.  The silence of MUC2 mRNA induced by promoter hypermethylation associated with HBV in Hepatocellular Carcinoma.

Authors:  Yang Ling; Jing Zhu; Lu Gao; Yongping Liu; Changtai Zhu; Rong Li; Lixin Wei; Changsong Zhang
Journal:  BMC Med Genet       Date:  2013-01-25       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.